While it might seem unlikely, the stage for this disruption was set during an episode of The Dr. Oz Show. Semaglutide, Novo Nordisk’s GLP-1 receptor agonist, was initially developed for diabetes management and later explored for its potential to treat Alzheimer’s and dementia. However, it was on Dr. Oz’s popular talk show that the weight loss properties of the drug—marketed under the brand name Ozempic—became the focus, sparking a viral craze that would ripple across the healthcare industry.
Fast forward to today, and what began as a simple mention on a daytime talk show has evolved into one of the most significant healthcare phenomena since the onset of the COVID-19 pandemic. The rise of obesity drugs has caused a shake-up in various sectors, with ramifications being felt across the medtech industry. This has ushered in what many call the Ozempic era—a new age in weight loss treatments that is reshaping the healthcare landscape.
Obesity is one of the most pressing public health challenges of our time. Globally, nearly 1 in 8 people (roughly 1 billion individuals) are living with obesity. The factors driving this epidemic are multifaceted, with sedentary lifestyles, poor diets, and environmental influences playing a significant role. For those struggling to manage their weight through traditional methods like diet and exercise alone, many turn to medical interventions.
Historically, surgical weight loss solutions have been the go-to option for patients who are severely obese and unable to manage their condition with lifestyle changes alone. The field has evolved significantly from the early days of open bariatric surgery to the advent of minimally invasive techniques. Bariatric surgeries, particularly minimally invasive procedures, are projected to continue their upward trajectory.
According to LSI’s Global Surgical Procedure Volumes database, the number of minimally invasive bariatric surgeries performed worldwide is expected to double by 2030. In 2023 alone, around 793,000 of these procedures were carried out globally, with that number set to increase at a 7.5% compound annual growth rate (CAGR), reaching an estimated 1.14 million surgeries by 2028. Prior to the widespread availability of obesity medications like semaglutide and tirzepatide, bariatric surgery had been the fastest-growing general surgery category by volume. The ongoing question remains: how will these new medications influence those numbers in the coming years?
Among the countries where bariatric surgeries are most common, Turkey, India, and China are experiencing the fastest growth. This growth highlights a global trend toward seeking more effective ways to combat obesity, though the rise of obesity medications introduces new variables that will continue to shape these patterns.
One of the most immediate impacts of these obesity drugs on the medtech industry is the slowdown in bariatric surgery procedures. Major players like Intuitive Surgical and Johnson & Johnson have reported noticeable declines in bariatric surgeries as patients increasingly opt for weight loss injections over the more invasive surgical route.
The appeal of these drugs is undeniable: they offer patients a relatively quick, low-effort path to weight loss. The introduction of semaglutide and tirzepatide as weight loss solutions has taken the healthcare world by storm. However, while these drugs have shown promise in helping patients lose weight, their long-term effectiveness is still under scrutiny.
Obesity medications like Ozempic typically lead to weight loss of 5-10% of total body weight, which, while helpful, may not be enough for all patients, especially those who are severely obese. On the other hand, bariatric surgery has a track record of producing far more significant, long-lasting results. Patients who undergo bariatric procedures often experience weight loss in the range of 40-80%, with results that are generally sustained over the long term.
This raises an important question for healthcare providers, medtech companies, and patients alike: Are obesity drugs simply a quick fix, or can they genuinely replace the need for surgery? While these drugs provide a much less invasive option, they fall short in delivering the same level of dramatic, long-lasting weight loss that bariatric surgery can offer, particularly for patients with more severe obesity-related health conditions.
To better understand this dynamic, let’s look at one specific area where this shift is already taking hold: pediatric obesity. In 2023, the American Academy of Pediatrics updated its treatment guidelines for pediatricians, encouraging them to consider weight loss surgery for children who are struggling with obesity. This change highlights the growing recognition of the need for more aggressive treatment options for young patients who may benefit from the long-term effects of surgical weight loss solutions.
Despite the rise of obesity medications, many experts in the medtech and healthcare fields are quick to point out that drugs alone will not solve the obesity crisis. In fact, there are still significant barriers to consider when it comes to the long-term success of these weight loss medications. Medications like Ozempic may offer a temporary solution, but for patients with more severe obesity, bariatric surgery remains the gold standard in terms of effectiveness and sustainability.
The real challenge lies in finding a balance. While some patients may benefit from the weight loss achieved through medication, others will require surgery to achieve lasting, meaningful results. The future of obesity treatment will likely involve a combination of medical weight loss solutions and surgery tailored to the individual patient’s needs.
Medtech companies—particularly those in the field of bariatric surgery—will need to adapt to these changing dynamics. This may mean investing in new technologies that can complement drug treatments or enhance the patient experience with bariatric surgery. For example, innovations in minimally invasive techniques, robotic surgery, and post-surgical care could help patients recover more quickly and experience better outcomes, even as weight loss medications gain popularity.
As the market for obesity drugs continues to grow, so too will the need for ongoing analysis and adaptation in the medtech field. It’s clear that obesity drugs like Ozempic are here to stay, but their full impact on bariatric surgery and other weight loss interventions remains to be seen.
One of the biggest questions on the horizon is: how long will the demand for these medications continue to rise? Will they remain a dominant force in the weight loss industry, or will patients eventually see diminishing returns as they rely on drugs alone for weight management? The full impact of the Ozempic era on bariatric surgery and other weight loss interventions is still unfolding, and the medtech industry will need to stay adaptable to these changes.
At the same time, surgical weight loss solutions will continue to evolve. New technologies, such as minimally invasive procedures, will ensure that bariatric surgery remains a viable option for those who need it. The future of obesity treatment will likely include a combination of drugs, surgery, and lifestyle changes, each playing a role in helping patients achieve lasting health improvements.
Gain access to the latest data and insights driving the medtech industry. Explore our Global Procedure Volumes Database to stay informed on key market trends and make data-driven decisions.
Looking for customized solutions? Reach out to our team of experts to discover how LSI’s Market Intelligence services can help you navigate industry changes and stay ahead of the competition.
Schedule an exploratory call
Request Info© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
.png)
.png)
